These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21517752)

  • 1. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
    Cesario A; Rocca B; Rutella S
    Curr Med Chem; 2011; 18(15):2263-71. PubMed ID: 21517752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
    Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
    Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
    Gostner JM; Becker K; Überall F; Fuchs D
    Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
    Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
    Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDO1, Cancer and Cancer-Associated Inflammation.
    Rutella S
    Curr Med Chem; 2011; 18(15):2204. PubMed ID: 21517760
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of indoleamine 2,3-dioxygenase in health and disease.
    Yeung AW; Terentis AC; King NJ; Thomas SR
    Clin Sci (Lond); 2015 Oct; 129(7):601-72. PubMed ID: 26186743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases.
    Filippini P; Del Papa N; Sambataro D; Del Bufalo A; Locatelli F; Rutella S
    Curr Med Chem; 2012; 19(31):5381-93. PubMed ID: 22963664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
    Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
    World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the IDO1 pathway in cancer: from bench to bedside.
    Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
    J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific in situ detection of murine indoleamine 2, 3-dioxygenase.
    Thomas S; DuHadaway J; Prendergast GC; Laury-Kleintop L
    J Cell Biochem; 2014 Feb; 115(2):391-6. PubMed ID: 24123235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDO Expression in Cancer: Different Compartment, Different Functionality?
    Meireson A; Devos M; Brochez L
    Front Immunol; 2020; 11():531491. PubMed ID: 33072086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues.
    Thomas S; Laury-Kleintop L; Prendergast GC
    Methods Enzymol; 2019; 629():219-233. PubMed ID: 31727242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial watch: IDO inhibitors in cancer therapy.
    Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
    Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses.
    Merlo LMF; DuHadaway JB; Montgomery JD; Peng WD; Murray PJ; Prendergast GC; Caton AJ; Muller AJ; Mandik-Nayak L
    Front Immunol; 2020; 11():1861. PubMed ID: 32973768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.
    Prendergast GC; Chang MY; Mandik-Nayak L; Metz R; Muller AJ
    Curr Med Chem; 2011; 18(15):2257-62. PubMed ID: 21517753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
    Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
    Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
    Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
    Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
    Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
    Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
    Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
    Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.